港股異動 | 騰盛博藥-B(2137.HK)高開超3% 宣佈用於治療產後抑鬱症的長效單次注射療法BRII-296的1期研究頂線結果
格隆匯9月27日丨騰盛博藥-B(2137.HK)高開3.11%,報5.96%。該公司昨日盤後宣佈公司正在開發用於治療產後抑鬱症("PPD")的長效單次注射療法BRII-296的1期研究頂線結果。研究數據表明,單次肌內("IM")注射600mg的BRII-296實現了線性劑量、早期藥物吸收、逐漸和延長釋放曲線,而無需劑量滴定或逐漸減少,為在該劑量下實現PPD治療的臨牀療效打下堅實基礎。選定的劑量方案將在預計於今年開展的2期臨牀試驗中進行評估。BRII-296是一種新型γ-氨基丁酸A受體陽性變構調節劑,具有獨特的長效劑型,無需停止哺乳,並使藥物在患者結束注射後數週內有效。BRII-296旨在快速、充分且持續地控制PPD的抑鬱症狀,相較於現有的治療選擇,BRII-296可能具有實質性的臨牀優勢。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.